Comparing Fennec Pharmaceuticals (NASDAQ:FENC) & Mosaic ImmunoEngineering (OTCMKTS:CPMV)

Mosaic ImmunoEngineering (OTCMKTS:CPMV) and Fennec Pharmaceuticals (NASDAQ:FENC) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk and valuation.

Institutional and Insider Ownership

55.5% of Fennec Pharmaceuticals shares are held by institutional investors. 81.0% of Mosaic ImmunoEngineering shares are held by company insiders. Comparatively, 11.0% of Fennec Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Mosaic ImmunoEngineering and Fennec Pharmaceuticals”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mosaic ImmunoEngineering	N/A	N/A	-$1.01 million	($0.15)	-6.67
Fennec Pharmaceuticals	$21.25 million	7.80	-$16.05 million	($0.10)	-60.39

Mosaic ImmunoEngineering has higher earnings, but lower revenue than Fennec Pharmaceuticals. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than Mosaic ImmunoEngineering, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Mosaic ImmunoEngineering has a beta of 0.01, indicating that its stock price is 99% less volatile than the S&P 500. Comparatively, Fennec Pharmaceuticals has a beta of 0.27, indicating that its stock price is 73% less volatile than the S&P 500.

Profitability

This table compares Mosaic ImmunoEngineering and Fennec Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mosaic ImmunoEngineering	N/A	N/A	-1,371.05%
Fennec Pharmaceuticals	-2.30%	-53.38%	-2.08%

Analyst Recommendations

This is a breakdown of recent ratings for Mosaic ImmunoEngineering and Fennec Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mosaic ImmunoEngineering	0	0	0	0	0.00
Fennec Pharmaceuticals	0	0	3	1	3.25

Fennec Pharmaceuticals has a consensus price target of $13.67, suggesting a potential upside of 126.27%. Given Fennec Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Fennec Pharmaceuticals is more favorable than Mosaic ImmunoEngineering.

Summary

Fennec Pharmaceuticals beats Mosaic ImmunoEngineering on 9 of the 14 factors compared between the two stocks.

About Mosaic ImmunoEngineering

Mosaic ImmunoEngineering, Inc., a development-stage biotechnology company, focuses on developing and commercializing immunomodulator platform technology for the treatment of cancer and infectious diseases in humans and for veterinary use. Its lead immunotherapy product candidate, MIE-101, a nanoparticle-based treatment derived from cowpea mosaic virus, which is non-infectious in humans and animals. The company was founded in 2020 and is based in Novato, California.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.